Mesa Laboratories, Inc. (NASDAQ:MLAB) (“we”, “Mesa” or the “Company”), a global leader in the design and manufacturing of critical quality control solutions for the pharmaceutical, healthcare, and medical device industries, today announced the acquisition of substantially all of the assets (other than current assets) and certain liabilities related to Belyntic GmbH’s (“Belyntic”) peptide purification business. “The acquisition of Belyntic’s peptide purification products provide Mesa with a natural complement to our peptide synthesis business by adding an advantaged consumables product line. The combination will enhance Mesa’s focus on the biopharmaceutical market to support faster therapeutic development.” said Gary Owens, President and Chief Executive Officer of Mesa.
Read the full article: Mesa Labs Acquires Belyntic’s Peptide Purification Business //
Source: https://www.globenewswire.com/news-release/2022/11/17/2558167/30771/en/Mesa-Labs-Acquires-Belyntic-s-Peptide-Purification-Business.html